Geo Vax Labs, Inc. GOVX
We take great care to ensure that the data presented and summarized in this overview for GeoVax Labs, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GOVX
Top Purchases
Top Sells
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Insider Transactions at GOVX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2024
|
David A Dodd President, CEO |
BUY
Open market or private purchase
|
Direct |
8,209
+30.55%
|
$16,418
$2.27 P/Share
|
|
Feb 21
2024
|
David A Dodd President, CEO |
BUY
Open market or private purchase
|
Direct |
520
+4.74%
|
$1,040
$2.15 P/Share
|
|
Feb 07
2024
|
Mark Reynolds CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+21.71%
|
$4,000
$2.77 P/Share
|
|
Dec 22
2023
|
Kelly T. Mc Kee Jr. Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
6,944
+16.25%
|
$0
$0.36 P/Share
|
|
Sep 25
2023
|
Kelly T. Mc Kee Jr. Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
9,653
+25.08%
|
$0
$0.52 P/Share
|
|
Aug 25
2023
|
David A Dodd President, CEO |
BUY
Open market or private purchase
|
Direct |
35,087
+19.06%
|
$0
$0.57 P/Share
|
|
Aug 18
2023
|
Mark Reynolds CFO |
BUY
Open market or private purchase
|
Direct |
10,000
+11.34%
|
$0
$0.52 P/Share
|
|
Apr 24
2023
|
David A Dodd President, CEO |
BUY
Open market or private purchase
|
Direct |
32,000
+21.94%
|
$0
$0.64 P/Share
|
|
Apr 20
2023
|
Mark Reynolds CFO |
BUY
Open market or private purchase
|
Direct |
8,000
+10.5%
|
$0
$0.63 P/Share
|
|
Sep 21
2022
|
Randal D Chase Director |
BUY
Open market or private purchase
|
Direct |
10,000
+21.45%
|
$10,000
$1.1 P/Share
|
|
Jul 01
2022
|
John W. Sharkey VP, Business Development |
BUY
Open market or private purchase
|
Direct |
1,000
+25.91%
|
$0
$0.82 P/Share
|
|
Jun 27
2022
|
Kelly T. Mc Kee Jr. Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,464
+18.88%
|
$4,464
$1.12 P/Share
|
|
Jun 21
2022
|
Randal D Chase Director |
BUY
Open market or private purchase
|
Direct |
10,000
+27.31%
|
$10,000
$1.21 P/Share
|
|
May 05
2022
|
Kelly T. Mc Kee Jr. Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
9,722
+39.77%
|
$0
$0.72 P/Share
|
|
May 04
2022
|
Kelly T. Mc Kee Jr. Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,999
+50.0%
|
$0
$0.71 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 72.4K shares |
|---|